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Class I/II hybrid iODN
immunosuppression
a b s t r a c t
We designed class I/II hybrid inhibitory oligodeoxynucleotides (iODNs), called iSG, and found that the
sequence 5′-TTAGGG-3′, which has a six-base loop head structure, and a 3′-oligo (dG)3–5 tail sequence are
important for potent immunosuppressive activity. Interestingly, splenocytes isolated from ovalbumin
(OVA)-immunized mice and treated with iSG3 showed suppression of not only interleukin (IL)-6, IL-
12p35, IL-12p40, and interferon (IFN) γ mRNA expression, but also IL-4 and IL-13 mRNA expression.
Thus, both Th2 and Th1 immune responses can be strongly suppressed by iODNs in splenocytes from
allergen-immunized mice, suggesting usefulness in the treatment of diseases induced by over-active
immune activation.
C© 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. Open access under 
CC BY-NC-ND license.1. Introduction
Diseases characterized by persistent immune activation can be
prevented or treated with inhibitory/suppressive oligodeoxynu-
cleotides (iODNs) in animal models. Immune cells respond to bac-
terial DNA containing unmethylated CpGmotifs via Toll-like receptor
9 (TLR9) [1]. Synthetic oligodeoxynucleotides (ODNs) containing un-
methylated CpG motifs stimulate a strong innate immune response
[2]. This stimulation can be abrogated by either removing the CpG
ODNs or adding iODNs [3]. Trieu et al. have provisionally categorized
iODNs into four classes (class I, II, III, and IV) based on sequence and
probablemodeof action [4]. Class I iODNs (suchasH154) areG-stretch
ODNs and are TLR9-speciﬁc competitors [3,5]. Class II iODNs (such
as A151) have telomeric repeats, are TLR9-independent inhibitors ofAbbreviations: ODN, oligodeoxynucleotide; IL, interleukin; TLR, Toll-like receptor;
PS, phosphorothioate; PO, phosphodiester; OVA, ovalbumin; ELISA, enzyme-linked im-
munosorbent assay; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide; IFN, interferon; Th1 cell, type 1 helper T cell; Th2 cell, type 2 helper T cell; STAT,
signal transducer and activator of transcription
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naling [6], and are potent suppressors of immune responses. Because
class II ODNs are generally synthesized as 24-base phosphorothioate-
modiﬁed ODNs (PS-ODNs), they also fall into the category of class
IV iODNs, which are deﬁned as long PS-ODNs that inhibit TLR9 re-
sponses in a non-sequence-speciﬁc manner. Class III iODNs include
oligo-(dG), which forms a four-stranded structure and inhibits DNA
uptake. The class I G-rich motifs show the most promise as selective
and potent TLR9 inhibitors for therapeutic applications [3]. However,
there are no reports of an anti-Th2 immune response following treat-
ment with iODNs. In this study, we designed a class I (H154) and class
II (A151) hybrid iODN, which we named iSG and that includes the
telomeric motif 5′-TTAGGG-3′. We analyzed the immune activity of
iSG 3′-oligo (dG)0–7 tail variants (iSG0, 1, 2, 3, 4, 5, 6, and 7) in mouse
splenocytes. We identiﬁed iSG3, 4, and 5 as inducing strong immuno-
suppression and requiring a particular secondary structure. Finally,
we investigated the effects of Th2 immunosuppressive activity by
iSG3 in immune cells from ovalbumin (OVA)-immunized mice.
2. Materials and methods
2.1. Reagents
Endotoxin-free desalted PS or phosphodiester (PO) bond ODNs
were synthesized by Integrated DNA Technologies, Inc. (Coralville,
IA, USA). The ODNs were reconstituted in endotoxin-free water and
passed through a 0.22-μm pore microﬁlter (Nihon Millipore K.K.,. Open access under CC BY-NC-ND license.




ODN1555 (CpG ODN) GCTAGACGTTAGCGT [7]
ODN1612 (GpC ODN) GCTAGAGCTTAGGCT [7]
H154 (class I iODN) CCTCAAGCTTGAGGGG [3]
H154M (H154 mutation) CCTCAAGCTTGACCCC This study
A151 (class II iODN) TTAGGGTTAGGGTTAGGGTTAGGG [6]
A151M (A151 mutation) TTACCCTTACCCTTACCCTTACCC This study
Class I/II hybrid iODNs iSG variants
iSG0 CCTCATTAGGGTGA This study
iSG1 CCTCATTAGGGTGAG This study
iSG2 CCTCATTAGGGTGAGG This study
iSG3 CCTCATTAGGGTGAGGG This study
iSG4 CCTCATTAGGGTGAGGGG This study
iSG5 CCTCATTAGGGTGAGGGGG This study
iSG6 CCTCATTAGGGTGAGGGGGG This study
iSG7 CCTCATTAGGGTGAGGGGGGG This study
iSG3M (iSG3 mutation) CCTCATTACCCTGACCC This study
Tokyo, Japan). Mouse splenocytes were treated with an equimolar
mixture containing mouse prototype CpG ODN 1555 (ODN1555) [7,8]
plus negative control GpC ODN 1612 (ODN1612) [7,8], iODN class I
H154 [3], iODN class II A151 [6,9], or iODN class I/II hybrid iSG0, 1,
2, 3, 4, 5, 6, or 7 (Table 1). ODN1555 previously shown to be a potent
stimulator of innate and adaptive immunity in mouse [7,8].
2.2. Mice and OVA-immunized mice
Pathogen-free male C57BL/6 mice (5 weeks of age) and BALB/c
mice (5 weeks of age) were purchased from Japan SLC (Shizuoka,
Japan) and kept under temperature- and light-controlled conditions.
Mice were given a standard diet of Labo MR Breeder (Nihon Nosan
Co., Kanagawa, Japan) and sterilewater ad libitum. After a preliminary
period of 1 week, BALB/c mice (6 weeks of age, n = 4) were intraperi-
toneally sensitized once weekly for 3 weeks with 100 μg OVA (Sigma,
St. Louis, MO, USA) and alum adjuvant (allergen/adjuvant ratio of
1:20). Mice were used for the study at 8 weeks of age. All experimen-
tal procedures were carried out in accordance with the Regulations
for Animal Experimentation of Shinshu University, and the animal
protocol was approved by the Committee for Animal Experiments of
Shinshu University. Based on national regulations and guidelines, all
experimental procedures were reviewed by the Committee for An-
imal Experiments and ﬁnally approved by the president of Shinshu
University.
2.3. Cells and cell culture
Mouse splenocytes were prepared using standard methods
[10,11]. Cellswere cultured in triplicatewells of a 24-well plate (Nalge
Nunc International K.K., Tokyo, Japan) at a ﬁnal concentration of 2
× 106 cells/well (total 1 mL/well) in complete RPMI 1640 medium
(Sigma-Aldrich) supplementedwith 10% fetal calf serum (Sigma), 100
U/mL penicillin, 100 mg/mL streptomycin, 25 mmol/L HEPES, 1.0
mmol/L sodium pyruvate, nonessential amino acids, and 0.0035% 2-
mercaptoethanol.
2.4. Real-time quantitative PCR analysis
Total RNA was isolated from ODN-stimulated mouse splenocytes,
treated with RNase-free DNase I (Roche, Lewes, UK) for 10 min at 37
◦C, and then heat inactivated at 70 ◦C for 15 min [10–12]. The cDNAs
were prepared by reverse transcription from 1 μg total RNA using
a PrimeScript
®
RT reagent kit (TaKaRa Bio Inc., Tokyo, Japan). An
equivalent volume of cDNAwas used for quantiﬁcation of various cy-
tokine cDNAs with real-time quantitative PCR using a Thermal Cycler
Dice
®
Real Time System (TaKaRa Bio Inc., Tokyo, Japan). Fluorescent
real-time quantitative PCRswere performedwith SYBR Premix Ex Taq
(TaKaRa Bio Inc., Tokyo, Japan) using speciﬁc primers, with each re-
action containing 5 ng cDNA in 25 μL. Primers for β-actin, interleukin
(IL)-4, IL-6, IL-12p35, IL-12p40, IL-13, and interferon gamma (IFNγ)
were purchased fromTaKaRa Bio Inc. The PCR cycling conditionswere
10 s at 95 ◦C, followed by 40 cycles of 5 s at 95 ◦C and 30 s at 60 ◦C. As
a control, poly-(A)+RNA samples were used as templates to check for
the presence of contaminating genomic DNA. The sensitivity of the
reaction and ampliﬁcation of contaminating products such as the ex-
tension of self-annealed primers were evaluated by amplifying serial
dilutions of cDNA. For cross-sample comparison of results obtained
following various treatments, cytokine mRNA levels were ﬁrst nor-
malized to mRNA levels for β-actin. The results represent the means
± SD of three independent experiments.
2.5. Cytokine enzyme-linked immunosorbent assay (ELISA)
IL-6 levels in cell culture supernatants 48 h after various treat-
ments were quantiﬁed using a commercially available ELISA kit
(Quantikine mouse IL-6; R&D Systems, Minneapolis, MN, USA) ac-
cording to the manufacturer’s instructions.
2.6. Secondary structural analysis of iODNs
The secondary structures of iODNs (H154, A151, and iSG variants)
were analyzed with CentroidFold software [13,14]. The detailed rela-
tionship between their secondary structure and immunosuppressive
activity was further analyzed in this study.
2.7. Cell proliferation assay
ODN-mediated suppression was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT:
Sigma-Aldrich) assay. Cells were seeded in 96-well plates at a
density of 2 × 105 cells/well. The cultures were then exposed to
3.0 μM ODN1555 + 3.0 μM control ODN1612 or iODNs for 48 h. As a
positive control, the cultures were exposed to 100 μg/mL Blasticidin
S HCl (Invitrogen, Grand Island, NY, USA), which is a nucleoside
antibiotic isolated from Streptomyces griseochromogenes that inhibits
protein synthesis in both prokaryotic and eukaryotic cells, and is
thus cytotoxic. The MTT assay was performed as described [9].
Brieﬂy, 100 μL medium containing MTT (0.5 mg/mL) was added to
the washed cells for 2 h. Non-internalized MTT was then washed
away, and the cells were lysed by adding 50 μL dimethylsulfoxide
(Sigma-Aldrich), which released the MTT internalized by viable
cells. The MTT concentration was measured colorimetrically, and
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cell proliferation was determined as the optical density at 565 nm
(OD565) of treated/untreated cultures (medium control = 100%).
2.8. Statistical analysis
Statistical analyseswere performed usingMedCalc, version 9.3.7.0
(MedCalc Software, Mariakerke, Belgium) and S-Plus (Version 7, In-
sightful Corp, Seatle, WA, USA). All tests were two-sided; probability
values less than 0.01 were considered signiﬁcant. All values are ex-
pressed as means ± SD unless otherwise noted.
3. Results
3.1. Immunosuppressive activity of class I/II hybrid iODN in mouse
immune cells.
To investigate the immunosuppressive activity of the class I/II
hybrid iODN iSG3, we ﬁrst examined the inhibition of IL-6 mRNA ex-
pression in mouse splenocytes stimulated with ODN1555 (Fig. 1). The
activity of iSG3 in suppressing IL-6 mRNA expression in splenocytes
was compared with the activity of H154 and A151, both of which
are known for their strong immunosuppressive activity. Splenocytes
were treated with immunostimulatory ODN1555 (3.0 μM) plus dif-
ferent concentrations of ODN1612 (negative control), H154, A151, or
iSG3. The iODNs (H154, A151, and iSG3) suppressed IL-6 mRNA ex-
pression in a dose-dependentmanner, with high immunosuppressive
activity at a concentration of 3.0 μM. Fig. 1A shows that iSG3 induced
signiﬁcantly stronger suppression of IL-6 mRNA than H154 or A151
(0.1–3.0μM) in this experimental system (Fig. 1A). To further examine
the suppressive effect of iSG3, we stimulated the cells with ODN1555
and also added ODN1612, iSG3 (Phosphorothioated bond, PS), or iSG3
(Phosphodiester bond, PO). As shown in Fig. 1B, IL-6 mRNA expres-
sion was also strongly suppressed by iSG3 (PS). On the other hand,
no suppressive effect was seen with iSG3 (PO). Essentially the same
observation was seen when ELISA was used to measure the induction
of IL-6 secretion (data not shown). Thus, iSG3wasmore potent at sup-
pressing IL-6 expression than A151 andH154 in CpGODN-stimulated
splenocytes.
We next analyzed the relationship between the number of bases
in the 3′-oligo (dG) n tail of iSG and IL-6 suppressive activity and cell
proliferation in cells stimulated with ODN1555 (Fig. 1C and Supple-
mental Fig. 1). The cultures were exposed to 3.0 μM ODN1555 + 0.1
or 3.0 μM iODNs or control ODN1612. The concentrations of IL-6 in
the supernatants were measured with ELISA (Supplemental Fig. 1B).
Interestingly, a 3′-oligo (dG)3,4,5 tail (iSG3, iSG4 and iSG5) produced
strong immunosuppression of IL-6 mRNA (Fig. 1C). Results of IL-6 se-
cretion were similar when measured with ELISA (Supplemental Fig.
1A and B). We also examined the cell proliferation of splenocytes
treated with 3.0 μM control ODN (ODN1612) or iODNs (A151, H154,
and iSG3) that were stimulated with 3.0 μM ODN1555 (Supplemen-
tal Fig. 2). The cell proliferation (%, medium control = 100%) indices
of cells treated with H154 (167.0 ± 10.1%), A151 (224.6 ± 14.9%),
and iSG3 (154.7 ± 8.6%) were signiﬁcantly lower than that of cells
treated with ODN1555 + ODN1612 (488.3 ± 19.4%) (Supplemental Fig.
2). These indices were higher than the medium control (100%). These
results suggest that iODNs did not kill cells, although iSG3 did inhibit
the cell proliferation seen with CpG ODN stimulation.
3.2. Strong immunosuppression by iSG3 requires a speciﬁc secondary
structure
We determined the secondary structure of the iODNs using Cen-
troidFold software [13,14]. To evaluate the importance of iSG se-
quences, we used the software to draw the secondary structure of
A151 and H154 (Fig. 2). The iSG variants contain six bases that form a
loop structure similar to A151 and H154 (Fig. 2). In the iSG from class
Fig. 1. Analysis of IL-6 mRNA expression in mouse splenocytes with real-time quanti-
tative PCR. Mouse splenocytes (2 × 106 cells/mL)were pre-incubated inmedium for 3
h prior to exposure to 3.0 μMODN1555 plus ODN1612 or iODN for 6 h (A–C). H154, A151,
and iSG3 (0.0001–3.0 μM) were used to determine the optimal concentration for the
suppressive activity of iODNs (A). ODN1555 (3 μM) plus 3.0 μM ODN1612, iSG3 (PS), or
iSG3 (PO) were added to examine the suppressive effect of their phosphorothioate (PS)
bond or phosphodiester (PO) bond subtypes (B). The suppressive activity of iSG 3′-oligo
(dG)0–7 tail variants (iSG0, 1, 2, 3, 4, 5, 6, and 7) in mouse splenocytes (C). IL-6 mRNA
expression in mouse splenocytes treated with 3.0 μM ODN1555 and 3.0 μM iODNs. Re-
sults are shown as the ratio of IL-6 mRNA levels (normalized to β-actin; see Section 2 )
in stimulated versus non-treated cells, as well as the IL-6 level in the medium control
(C). The results represent the means ± SD of three independent experiments. Values
with different letters (i.e., a, b, c, d, and e) were signiﬁcantly different (P < 0.01). All
assays were carried out at least three independent times in triplicate.
I/II hybrid iODNs, 5′-TTAGGG-3′ sequences are speciﬁcally found in
the loop similar to A151 (Fig. 2). To identify the iSG3 core motifs
responsible for the immunosuppressive activities, we examined the
suppressive effect of mutated iODNs of H154, A151, and iSG3, which
were named H154M, A151M, and iSG3M, respectively. The TTTAGGG
sequence(s) in the A151 and iSG3 sequence(s) was/were changed to
TTACCC (Table 1 and Fig. 2). The 3′-G tail sequence inside the H154
and iSG3 sequence was changed to a 3′-C tail (Table 1 and Fig. 2).
We examined the ability of mutated iODNs to suppress IL-6 mRNA
expression in mice splenocytes (Fig. 3). The mutated iODNs (H154M,
A151M, and iSG3M) did not suppress IL-6 mRNA expression when
TTAGGG and the 3′-G tail sequences were changed to TTACCC and a
3′-C tail (Fig. 3). The large hairpin loop structure formed by TTACCC
in iSG3M did not show a potent suppressive effect (Figs. 2 and 3).
H154M and A151M without TTAGGG and the 3′-G tail structure also
showed low suppression. This revealed that a TTAGGG loop and/or a
3′-G tail structure are necessary for strong immunosuppression.
3.3. Th1 and Th2 double immunosuppression by iSG3 in immune cells
from OVA-immunized mice
Weexamined the ability of iSG3 to suppress Th1- and Th2-type cy-
tokine expression in splenocytes isolated fromOVA-immunizedmice
(Fig. 4). The cultureswere exposed to 10μg/mLOVA+3.0μMnegative
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Fig. 2. Secondary structural analysis of iODNs. Secondary structures were predicted
with CentroidFold software. Pairs shown in red have a high probability of forming, pairs
in green have amediumprobability of forming, and pairs in blue have a low probability
of forming. The normalized scale showing a probability from 0 (dark blue) to 1 (red) is
shown on the lower right. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 3. Inﬂuence of the TTAGGG loop and/or 3′-G tail in the iODNs. The 3′-G tail of
the iODNs was changed to a 3′-C tail. The TTAGGG sequence was changed to TTACCC.
Results are shown as the ratio of IL-6mRNA levels (normalized toβ-actin; see Section 2
) in stimulated versus non-treated cells, as well as the IL-6 level in themedium control.
Values represent means, and error bars indicate the SD. The closed bars correspond to
the ODN1555 plus control or optimal iODN (ODN1612, H154, A151, and iSG3), and the
open bars show ODN1555 plus mutated iODNs (H154M, A151M, and iSG3M). Values
with different letters (i.e., a, b, c, d, and e) were signiﬁcantly different (P < 0.01). All
assays were carried out at least three independent times in triplicate.
control ODN1612, ODN1555, or iODNs (A151, H154, iSG3) for 72 h. OVA
+ ODN1612 strongly induced mRNA expression of Th2-type cytokines
such as IL-4 (Fig. 4A) and IL-13 (Fig. 4B), inﬂammatory cytokines such
as IL-6 (Fig. 4C), and Th1 cytokines such as IL-12p35, IL-12p40 (Fig.
4D and E), and IFNγ (Fig. 4F). OVA + ODN1555 also strongly induced
mRNA expression of Th1 cytokines such as IL-12p35 and IL-12p40
Fig. 4. Real-time quantitative PCR analysis of IL-4, IL-13, IL-6, IL-12p35, IL-12p40,
and IFNγ mRNA levels in splenocytes isolated from OVA-immunized mice that were
subsequently treated with 10 μg/mL OVA + 3.0 μM ODN1612, ODN1555, A151, H154, or
iSG3. Mouse splenocytes were pre-incubated in medium for 3 h prior to exposure to
OVA andODNs for 72 h. Expression of IL-4 (A), IL-13 (B), IL-6 (C), IL-12p35 (D), IL-12p40
(E), and IFNγ (F) mRNAs were determined with real-time quantitative PCR. Results are
shown as the ratio of cytokine mRNA levels (normalized to β-actin; see Section 2 ) in
stimulated versus non-treated cells, as well as the level in the medium control. Values
represent means, and error bars indicate the SD of three independent experiments.
Values with different letters (i.e., a, b, c, d, and e) were signiﬁcantly different (P< 0.01).
(Fig. 4D and E). In our preliminary study, ODN1555 strongly induced
IFNγmRNAafter 6–12hof stimulation. IFNγwasdownregulated after
24 h (data not shown) in the mouse immune cells. Interestingly, cells
stimulated with OVA + iSG3 for 72 h showed signiﬁcant suppression
of IL-4 and IL-13mRNA comparedwithOVA+ODN1612, A151, orH154
(Fig. 4A and B). In particular, A151 showed negligible suppression of
IL-13mRNA (Fig. 4B).Moreover, OVA+ iSG3 or A151 signiﬁcantly sup-
pressed IL-12p40 and IFNγ mRNA compared with OVA + H154 (Fig.
4E and F). Cells treatedwith OVA +A151 showed similarly suppressed
levels of IL-12p40 and IFNγ mRNA as cells treated with iSG3 (Fig. 4E
and F).
To monitor the immunosuppressive activity after iSG3 removal,
mouse splenocytes were exposed to 3.0 μMODN1612 or iSG3 for 24 h.
Cells were then washed with medium to remove the iSG3. Cells were
resuspended in medium with 3.0 μMODN1555 for 6 or 48 h. Interest-
ingly, immunosuppressive activity and inhibition of cell proliferation
were maintained in splenocytes after iSG3 was removed from the
culture (Supplemental Fig. 3).
4. Discussion
Previous studies revealed that iODNs inhibit the immune response
by blocking the stimulatory effects of CpG motifs [4,15]. In animal
models, iODNs can be used to prevent or treat diseases characterized
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by persistent immune activation, including collagen-induced arthri-
tis [16], inﬂammatory arthritis [5], silicosis [9], autoimmune neuritis
[17], papillomas [18], ocular inﬂammation [19], and toxic shock [20].
In this study, we examined the immune effect of iODNs in mouse im-
mune cells. The results indicated that the class I/II hybrid iODN, iSG3,
showed signiﬁcantly higher suppressionof proinﬂammatory cytokine
mRNAs than H154 or A151. To the best of our knowledge, there have
been no previous reports of suppression of Th2 immune responses by
iODNs. In splenocytes from OVA allergic model mice, treatment with
iSG3 reduced the expression of IL-4, IL-13, IL-12p40, and IFNγ mRNA
in 10 μg/mLOVA-treated cells. This class I/II hybrid iODN suppressed
not onlymRNA levels of several Th1- and Th2-type cytokines, but also
cell proliferation. iODNs can also inhibit several signal transduction
cascades related to the production of Th1 cytokines such as IFNγ and
IL-12 by binding and inhibiting the phosphorylation of STAT1, 3, and
4 proteins [20,21]. No effect was observed on STAT5 and 6. This effect
is independent of TLR9 and leads to the absence of a response to IL-12
and IFNγ in T cells and a subsequent transition to the Th2 phenotype
rather than Th1 [21]. However, we have shown that iSG3 downregu-
lated the expression levels of Th2 cytokines in allergen-treated cells
fromallergicmodelmice. Our studydemonstrated that iSG3 canblock
both Th1 andTh2 immune responsesmediated by allergen in immune
cells from allergic model mice.
The molecular mechanism by which class I/II hybrid iODNs such
as iSG3, 4, and 5 suppress immune responses remains unclear. No
information has been reported on the relationship between the sec-
ondary structure and immunosuppression by iODNs. Therefore, in
the present study, we focused on the role of the secondary structure
using CentroidFold software [13,14]. CentroidFold is a standard soft-
ware for predicting secondary structures and is useful for the func-
tional analysis of RNA, for helping design PCR primers and siRNA, and
leads to higher quality microarray probes [13,14]. We found that 3′-
oligo (dG)3–5 tail sequences are optimal for immunosuppression and
that 5′-TTAGGG-3′ with a six-base loop head structure is important
and possibly critical for potent immunosuppression. These structures
may be required for immunosuppression of the Th1- and Th2-type
immune responses.
Current studies show that iSG3had little effect on cell proliferation
in splenocytes, similar to the medium control, as assessed with the
MTT assay. Because we also established that splenocytes pretreated
with iSG3maintain the ability to suppress the immune response after
the iSG3 is washed out, the immunosuppression by iSG3 may be
due to inhibition of cell signaling. Although additional studies on the
relationship between iODNs and the iODN binding pocket of TLR9 or
other receptors are needed to elucidate the molecular mechanism of
iODN recognition, the current study emphasizes an important role in
immunosuppression for class I and II hybrid iODNs. Further detailed
studies are needed to elucidate the mechanism of this iODN-based
immunosuppressive drug candidate.
In summary, we found that 3′-oligo (dG)3–5 tail sequences are
optimal for immunosuppression and that a 5′-TTAGGG-3′ loop struc-
ture is important and possibly critical for potent immunosuppression.
These structures may be required for immunosuppression of the Th1
and Th2 immune responses.
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